Molecular Theranostic Center of Singapore

Molecular Theranostic Center of Singapore (MTCS) is a clinical-stage biotechnology company and a wholly owned subsidiary of the U.S.-based Molecular Targeting Technologies, Inc. (MTTI). The company is dedicated to developing innovative targeted radiotherapeutics for cancers with high unmet needs, particularly those prevalent in Asia such as nasopharyngeal cancer. MTCS utilizes the proprietary EvaThera platform, which incorporates Evans Blue dye derivatives to extend the biological half-life and enhance the tumor accumulation of radiopharmaceuticals. Its lead program, EBTATE (177Lu-DOTA-EB-TATE), is undergoing clinical evaluation for multiple indications including neuroendocrine tumors and nasopharyngeal cancer. The company maintains strong collaborative ties with the National University of Singapore and the National University Cancer Institute Singapore to drive its clinical programs.